現(xiàn)代脂質(zhì)三聯(lián)治療ppt課件-文庫吧資料
2025-01-22 11:38本頁面
【正文】 ? 3 ? = 3 ? 3 ? = 5 ? 5 ? 3 ? = 3 ? = 3 ? 3 ? = 3 LDL/HDL Responder Rates mg responder rate at 8 weeks (n = 941) Data on file Baseline after 8 weeks 5 High CHD risk Medium CHD risk Low CHD risk 8% 60% 32% 90% 9% 1% 35 3 LDL / HDL Moving patients into the safety area after 8 weeks (n = 187) Reaching Target with LDL/HDL Ratio Reduction OSE et al. Curr Med Res amp。85, 1: 37 “ Patients in the placebo group with triglyceride levels of ? 200 mg/dl and an LDL/HDL ratio of ? had by far the highest incidence of cardiac events” Gerd Assmann, Lipid Metabolism Disorders and Coronary Heart Disease, MMV Medizin Verlag, 1993 The Lipid Triad Expert Comments PROCAM “The greatest difference, in relative terms, between the groups with and without major coronary events was seen in the LDL/HDLratio” Assmann G, Cullen P and Schulte H。 Lipid Metabolism Disorders and CHD。 Lipid Metabolism Disorders and CHD。 Lipid Metabolism Disorders and CHD。 Lipid Metabolism Disorders and CHD。 Lipid Metabolism Disorders and CHD。 Am J Cardiol 1992。 85: 3745 AFCAPS/TEXCAPS Apo B/A1 Tertiles LDLC/HDLC Tertiles 1 0 1 0 Event Rate per 100 PatientYears of Risk Event Rate per 100 PatientYears of Risk ? ? ? ??.4101 GOTTO A et al. Circulation 2022。 79: 8 15. HDL C [mg / dl] 65 55 45 35 LDL Cholesterol mg / dl LDL Cholesterol mg / dl 12 10 8 6 4 2 0 100 130 160 190 0 1 2 3 Framingham Heart Study CAD risk as a function of LDLC and HDLC in men (50 to 70 y) CASTELLI WP. Am J Cardiol 1998。 341:410 0 6 31 4 35 30 25 20 15 10 5 0 5 10 Cholesterol LDLC HDLC Triglycerides Percent change pared to placebo at 1 year Secondary Prevention in 2531 men with low HDLC amp?，F(xiàn)代脂質(zhì)三聯(lián)治療 Introduction Part I Efficacy The Power to Reach Target Key Factor: + Differentiators: LDL Reduction TG
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1